Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia"
- Conditions
- Schizophrenia
- Interventions
- Drug: aripiprazole, olanzapine, quetiapine or risperidone
- Registration Number
- NCT04312503
- Lead Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
- Brief Summary
The aim of this study is observation, in an Italian real-world setting, of metabolic effects in patients with schizophrenia who will switch from any mono-therapy or poly-therapy antipsychotic regimen to monotherapy with lurasidone or to one of the other four most used atypical antipsychotics.
- Detailed Description
The aim of this study is the observation, in psychiatric Italian real-world settings, of metabolic effects, effectiveness, side effects and therapeutic adherence in patients with schizophrenia who switched, for any reason (efficacy, safety, metabolic problems, therapeutic adherence or patient's request), from any mono-therapy or poly-therapy antipsychotic regimen to monotherapy with lurasidone or with one of the four most used atypical antipsychotics in Italy (aripiprazole, olanzapine, quetiapine, risperidone). Patient's past medical and psychiatric history of the last 12 months will be also evaluated.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 95
- Patients with a diagnosis of schizophrenia according to DSM-5.
- Patients who gave their written consent for participation in the study and for personal data processing and willing to comply with all study procedures.
- Male and female patients ≥ of 18 years old at baseline.
- Patients treated or in treatment with any typical or atypical antipsychotic monotherapy or polytherapy.
- Patients switched from the pre-existing therapy to lurasidone, aripiprazole, olanzapine, quetiapine or risperidone in monotherapy within the preceding 2 weeks. The date of the switch is considered as baseline.
- Female patients who are pregnant or lactating
- Patients fulfilling DSM-5 criteria for diagnosis of bipolar disorder and/or dementia.
- Amphetamines and/or Opiates abuse or dependence , as defined by DSM-5 criteria.
- Patients with no history of antipsychotics use.
- Patients recruited in another study as follows:
- currently enrolled in any pharmacological or non-pharmacological, interventional or observational study:
- who participated in the last 30 days to any observational or no-profit interventional study;
- who participated in the last 12 months to any interventional commercially sponsored study.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description COHORT B: aripiprazole, olanzapine, quetiapine or risperidone) aripiprazole, olanzapine, quetiapine or risperidone Patients treated with other atipical antypsicothic as aripiprazole, olanzapine, quetiapine or risperidone) COHORT A: Lurasidone Lurasidone Patients treated with Lurasidone
- Primary Outcome Measures
Name Time Method Change in the metabolic parameters 4 weeks Change in metabolic syndrome in 3 of 5 parameters:
1. Arterial hypertension defined as. systolic pressure ≥ 130 mmHg and/or diastolic pressure ≥85 mmHg or treatment for hypertension.
2. Waist Circumference ≥ 90 cm in men or ≥ 80 cm in women.
3. Fasting Plasma Glucose ≥5.6 mmol/l and/or known treatment for hyperglycemia.
4. Triglycerides ≥1.7 mmol/l or medication for elevated triglycerides.
5. HDL Cholesterol ≤ 1.0 mmol/l in men and ≤1.3 mmol/l for women or taking medication.
- Secondary Outcome Measures
Name Time Method Retrospective investigation of the metabolic effects of switches to any atypical antipsychotic occurred in the previous 12 months 12 months before baseline (switch to any atypical antipsychotics) Change in metabolic syndrome in 3 of 5 parameters:
1. Arterial hypertension defined as. systolic pressure ≥ 130 mmHg and/or diastolic pressure ≥85 mmHg or treatment for hypertension.
2. Waist Circumference ≥ 90 cm in men or ≥ 80 cm in women.
3. Fasting Plasma Glucose ≥5.6 mmol/l and/or known treatment for hyperglycemia.
4. Triglycerides ≥1.7 mmol/l or medication for elevated triglycerides.
5. HDL Cholesterol ≤ 1.0 mmol/l in men and ≤1.3 mmol/l for women or taking medication.
Trial Locations
- Locations (18)
IRCCS Ospedale Policlinico San Martino
🇮🇹Genova, GE, Italy
P.O. Gaspare Rodolico - U.O.C. di Psichiatria
🇮🇹Catania, CT, Italy
A.O.U. San Luigi Gonzaga - S.C.D.U. di Psichiatria Regione Gonzole, 10
🇮🇹Orbassano, TO, Italy
Azienda Ospedaliera Universitaria Federico II - U.O. Psichiatria
🇮🇹Napoli, Italy
A.O.U. di Cagliari Corso Vittorio Emanuele II, 6 09124 Cagliari (CA)
🇮🇹Cagliari, CA, Italy
Ospedale S. Gerardo Università Bicocca Dipartimento di Salute Mentale
🇮🇹Monza, MB, Italy
Ospedale Luigi Sacco, S.C. Psichiatria 2
🇮🇹Milan, MI, Italy
III S.P.D.C. Azienda Ospedaliera di Padova 35128 Padova - (PD)
🇮🇹Padova, PD, Italy
AO Mater Domini U.O. Psichiatria
🇮🇹Catanzaro, CZ, Italy
Ospedale San Raffaele U.O.C. Psichiatria Generale e Riabilitazione
🇮🇹Milan, MI, Italy
Azienda Ospedaliero Universitaria Sant'Andrea
🇮🇹Roma, RM, Italy
Ospedali Riuniti SOD di Clinica Psichiatrica
🇮🇹Ancona, AN, Italy
DSM Dipartimento Salute Mentale
🇮🇹Lecce, LE, Italy
Ospedale Maggiore Policlinico di Milano U.O. C. di Psichiatria
🇮🇹Milan, MI, Italy
Azienda Ospedaliera - Universitaria Senese
🇮🇹Siena, Italy
Spedali Civili di Brescia Dipartimento di Salute Mentale 1
🇮🇹Brescia, BS, Italy
A.O.U. Ospedali Riuniti di Foggia - S.P.D.C. Viale Pinto 71121 Foggia (FO)
🇮🇹Foggia, FG, Italy
Clinica Von Sibenthal Via della Madonnina, 1
🇮🇹Genzano Di Roma, RM, Italy